Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-453 | TNBC | Luminal | Doxorubicin | TOP2 | TOP | 3.68 | uM | 10270.121 | 0.2089 | -0.7014 | 0.8235 | |
| MDA-MB-453 | TNBC | Luminal | Doxorubicin | TOP2 | TOP | 18.4 | uM | 10270.121 | 0.9580 | 0.8984 | 0.8235 | |
| MDA-MB-453 | TNBC | Luminal | Doxorubicin | TOP2 | TOP | 92 | uM | 10270.121 | 0.5192 | -0.0977 | 0.8235 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 7904.077 | 1.1184 | 1.1537 | 1.5112 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 7904.077 | 1.0611 | 1.0800 | 1.5112 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 7904.077 | 1.1184 | 1.1537 | 1.5112 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 7904.077 | 0.9628 | 0.9504 | 1.5112 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.147 | uM | 7904.077 | 1.0218 | 1.0287 | 1.5112 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.736 | uM | 7904.077 | 0.6554 | 0.5122 | 1.5112 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 3.68 | uM | 7904.077 | 0.2487 | -0.2036 | 1.5112 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 18.4 | uM | 7904.077 | 0.3061 | -0.0863 | 1.5112 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 92 | uM | 7904.077 | 0.0518 | -0.7178 | 1.5112 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7905.007 | 1.1527 | 1.3652 | 0.8475 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7905.007 | 0.7589 | 0.4443 | 0.8475 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7905.007 | 0.9771 | 0.9461 | 0.8475 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7905.007 | 1.0014 | 1.0034 | 0.8475 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7905.007 | 1.0652 | 1.1548 | 0.8475 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7905.007 | 0.5206 | -0.0743 | 0.8475 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7905.007 | 0.1480 | -0.7901 | 0.8475 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7905.007 | 0.0862 | -0.8891 | 0.8475 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7905.007 | 0.0026 | -0.9982 | 0.8475 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7906.007 | 0.6610 | 0.0250 | 0.6194 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7906.007 | 1.4010 | 2.4471 | 0.6194 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7906.007 | 1.3757 | 2.3470 | 0.6194 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7906.007 | 1.0785 | 1.2595 | 0.6194 |